The mRNA IP and Competitive Landscape Through One Year of the COVID-19 Pandemic–Part I | Rothwell, Figg, Ernst & Manbeck, P.C.
To embed, copy and paste the code into your website or blog: Shortly after we posted about Moderna, Inc.’s October 2020 pledge not to enforce its COVID-19-related patents during the pandemic, the United States Food & Drug Administration (FDA) granted emergency regulatory approval for two COVID-19 vaccines produced by Moderna and BioNTech (with Pfizer), making these groups the first to ever enter the commercial market with mRNA-based therapies. This little-known and never-before-approved mRNA technology has since been widely administered and represents a primary weapon being used to defeat t...
Source: jdsupra.com